- Home
- » Tags
- » GlaxoSmithKline
Top View
- Hikma Provides Update on Status of ANDA for Generic Advair Diskus®
- Template That Creates a Custom Pleading
- Other Statutory Disclosures Continued
- Viropharma Failure Leaves CMV Pipeline Looking Thin
- ESG Performance Summary 2019 About This Report
- How You Gained Power in Your Organization
- Glaxosmithkline STATISTICAL ANALYSIS PLAN Study Title: Post
- FTSE 100 Index Data As At: 31 August 2021 Bmktitle1 the FTSE 100 Is a Market-Capitalisation Weighted Index of UK-Listed Blue Chip Companies
- Viiv Healthcare Reports Landmark Phase III Studies for Dolutegravir
- Viropharma Incorporated 2010 Annual Report Over 200 Additional HAE Patients Chose Cinryze for Routine Prophylaxis in 2010
- List of RFR Referencing Syndicated and Bilateral Loans This Document
- Press Release First Quarter 2021
- GSK Annual Report 2019 01 Our Business Model Continued
- Fact Sheet for Healthcare Providers Emergency Use Authorization (Eua) of Sotrovimab
- GSK Annual Report 2005 01 However, Addressing This Challenge Is Something GSK Cannot “The Tragedies During the Year Brought Home to Me the Extent Do Alone
- Group Companies
- Ishares Core FTSE 100 UCITS ETF GBP (Dist)
- Glaxosmithkline (GSK) Achieves Approval for Nucala (Mepolizumab)
- Completed Acquisition by Shire Plc of Viropharma Incorporated
- 300 Years of GSK Three Centuries of Innovation
- Drug Companies Participating in MED-Project Stewardship Plan (February 9, 2017)
- Deborah L Penrod Tel 215 840 9943 [email protected] PO Box
- FTSE UK Capped 5% Indices Data As At: 31 August 2021 Bmktitle1 the FTSE UK Capped 5% Indices Represent 98% of the UK Market Capitalisation
- FTSE Factsheet
- Hikma Provides an Update on the Status of Its ANDA for Generic Advair Diskus®
- 2018 MED-Project Annual Report
- Glaxosmithkline Processes 90% of Its Invoices Electronically with Tungsten Network
- Glaxosmithkline Company Profile
- Ellen Petersen, Executive Coach and Consulting, LLC 610-636-3261; [email protected]
- Investor Information Information Investor Information
- Full Text (PDF)
- Glaxosmithkline Plc Notice of Annual General Meeting 2021
- The Largest Pharmaceutical Companies Worldwide Analysis of Key Financial Indicators for Fiscal Years 2017, 2018 and 2019 About the Study
- DR. E. ROBERT BECKER Retired Process Engineer – Environex DR
- View Complaint
- Viiv Healthcare Announces Positive Results from First Phase III Studies of Two-Drug HIV Treatment Regimen
- WELLBUTRIN Safely and Effectively
- Annual Report 2018 GSK Annual Report 2018
- Hikma Completes Its FDA Response for Generic Advair®
- Program Cover V6
- Issue of 50,000 Warrants Linked to the Ordinary Shares of Glaxosmithkline Pharmaceuticals Ltd
- Glaxosmithkline Research Triangle Park, NC 27709 Lamivudine Is
- 4Th Quarter 2013
- Glaxosmithkline Plc, of 1934, MAKING FINDINGS, and IMPOSING REMEDIAL SANCTIONS and a Respondent
- [email protected] • Simon Lowth, Chief Financial Officer
- IMITREX Safely and Effectively
- Glaxosmithkline Graphs
- GSK Group Company Names and Addresses
- Glaxosmithkline, Under Pressure, Cuts Price of AIDS Treatment for Poor
- Glaxosmithkline - Wikipedia
- Pdf Circular and Prospectus
- The Diagnosis and Management of Acute and Chronic Urticaria: 2014 Update
- Philadelphia Foundation Partners with Mayor's Office of Civic
- The Pennsylvania State University Schreyer Honors College
- Targacept and Glaxo Enters Into $1
- Glaxosmithkline Euro Medium Term Note Programme
- Viiv Healthcare Launches
- Pharma 2020: Challenging Business Models Which Path Will You Take? Table of Contents
- Hereditary Angioedema, Acquired C1 Inhibitor Deficiency, and Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- Hikma Provides an Update on the Status of Its ANDA for Generic Advair Diskus®